Bridget M. Kuehn | Authors


Genomic Profiling Provides Much-Needed Prognostic Data in Glioma

June 04, 2015

Results from a genomic and molecular analysis presented at the 2015 ASCO Annual Meeting and published in Acta Neuropathology indicate that low-grade gliomas may be classified into three distinct prognostic categories based on genomic data.

BRAF/MEK Combo Shows Overall Survival Benefit at 2 Years in Melanoma Patients

June 01, 2015

Patients with BRAF-mutant late-stage melanoma derive a lasting overall survival (OS) benefit from treatment with the combination of dabrafenib and trametinib compared with dabrafenib and placebo, according to the final results from the COMBI-d phase III double-blinded trial.